Table 2.
|
|
|
Relapsed |
Infection without |
|||
---|---|---|---|---|---|---|---|
Overall (n = 143) | Infection (n = 20) | relapse (n = 123) | |||||
Primaquine |
N |
(%) |
N |
(%) |
N |
(%) |
|
|
Yes |
114 |
79.7 |
16 |
80.0 |
98 |
79.7 |
|
Nil |
21 |
14.7 |
3 |
15.0 |
18 |
14.6 |
|
Unknown |
8 |
5.6 |
1 |
5.0 |
7 |
5.7 |
Primaquine dose |
|
|
|
|
|
|
|
|
Nil |
21 |
14.7 |
3 |
15.0 |
18 |
14.6 |
|
Low (<420 mg) |
50 |
35.0 |
9† |
45.0 |
41† |
33.3 |
|
High (≥420 mg) |
54 |
37.8 |
1† |
5.0 |
53† |
43.1 |
|
Unknown |
18 |
12.6 |
7 |
35.0 |
11 |
8.9 |
Dosage (mg) |
median |
(IQR) |
median |
(IQR) |
median |
(IQR) |
|
315 | (210–420) | 210 | (210–315) | 315 | (210–420) |
†(OR 11.6, 95% CI 1.5-519, p = 0.005).